Divi’s Labs Q2 results for the September quarter show net profit jumping 64% year-on-year to ₹1,127 crore, powered by stronger demand across its custom synthesis and generic API businesses. The Hyderabad-based pharma major also reported healthier margins as revenue climbed alongside profit. For a company that spends most of its life making chemical building blocks for other people’s medicines, this is a genuinely strong quarter.
Key Takeaways
- Divi’s Labs Q2 results show net profit at ₹1,127 crore, up 64% from roughly ₹687 crore a year earlier.
- Revenue also rose for the quarter, with the pace of profit growth outstripping sales growth — a sign of improving margins.
- Custom synthesis demand, including work tied to GLP-1 weight-loss and diabetes molecules, continues to be a key swing factor for the business.
- The numbers feed into a bigger India story: global drugmakers leaning harder on Indian API and CRAMS players as they diversify away from China.
Divi’s Labs Q2 Results: The Key Numbers
Let’s start with what actually moved. The headline from the Divi’s Labs Q2 results is simple: net profit at ₹1,127 crore, a 64% jump over the same quarter last year. That’s not a one-off spike either — it builds on a string of quarters where the company has been clawing back margin after a rough patch in FY24.
How Much Did Net Profit Rise?
Working backward from the 64% growth figure, Divi’s Laboratories would have posted a net profit of around ₹687 crore in the same quarter a year ago. That jump of roughly ₹440 crore in absolute terms is a big swing for a company of this size, and it shows up clearly once you line the two quarters side by side.
| Metric | Same Quarter Last Year | Latest Quarter | Change |
| Net Profit | ~₹687 crore | ₹1,127 crore | +64% |
| Revenue | Lower base | Higher, grew alongside profit | Positive, slower than profit growth |
| Margin trend | Under pressure | Improving | Expansion |
What About Revenue?
Revenue for the quarter also moved up, which is what you’d expect given the scale of the profit jump. What stands out, though, is that profit grew faster than sales — the classic sign of a business getting more efficient rather than just doing more volume. Better capacity utilisation at its Kakinada and Vizag units, along with a more favourable product mix, likely did a lot of the heavy lifting.
Why Did Profit Jump 64% in This Quarter?
A few things usually drive a quarter like this for a company like Divi’s Labs. First, custom synthesis — making a molecule on contract for a global innovator drugmaker — tends to carry fatter margins than plain generic APIs. Second, a stable rupee against the dollar helps an exporter like this one, since a big chunk of revenue is billed in foreign currency. Third, raw material costs for key starting materials have been relatively calmer compared to the volatile stretch of 2022-23.
There’s also a demand-side story worth flagging. Global pharma companies have been pushing harder on GLP-1 class drugs — the same family behind semaglutide-type weight-loss and diabetes treatments — and Indian CRAMS players with the right regulatory approvals have picked up meaningful contract manufacturing work in this space. Divi’s has talked about this opportunity on earlier earnings calls, and it’s plausible this pipeline is now showing up in the numbers.
How Is the Market Reading the Divi’s Labs Share Price?
Strong, clean beats like this one usually get rewarded, at least in the near term. Analysts tend to watch two things closely after a quarter like this: whether the margin improvement is sustainable, and whether management’s commentary on new molecule wins and capacity expansion backs up the optimism. Investors in pharma counters like Divi’s Laboratories also keep an eye on how the stock trades relative to the broader Nifty Pharma index, since sentiment in the sector often moves as a pack.
What Does This Mean for India’s API Export Story?
This is where the Divi’s Labs Q2 results tie into something bigger than one company’s balance sheet. India has spent the last few years trying to position itself as the credible alternative to China for active pharmaceutical ingredients and custom synthesis work — the so-called “China+1” strategy that global pharma majors have been quietly executing since the pandemic exposed how concentrated their supply chains were. Divi’s, founded by Murali K. Divi and built up over three decades into one of India’s largest API makers, as detailed on Divi’s Laboratories’ Wikipedia page, is one of the handful of Indian firms with the scale and regulatory track record to actually win that business rather than just talk about it.
That matters for policy too. The government’s production-linked incentive scheme for bulk drugs has been nudging companies to build fresh capacity at home instead of relying on imported intermediates, and a results season where a bellwether like Divi’s beats expectations gives that whole push a bit of credibility it didn’t have two years ago, when margins across the sector were under real strain from pricing pressure and high input costs.
How Does Divi’s Labs Compare With Pharma Peers This Season?
It helps to put this in context against the rest of the sector. Larger diversified players like Sun Pharma and Dr Reddy’s Laboratories lean more on branded formulations and the US generics market, so their quarterly swings often track drug pricing and launch timing in America. Pure API and CRAMS names like Laurus Labs sit closer to Divi’s business model, and the sector broadly has been recovering from the margin squeeze of 2022-23. Seen against that backdrop, a 64% profit jump isn’t just a good quarter in isolation — it’s a sign that the API and custom synthesis part of Indian pharma is genuinely back on its feet.
FAQ
What were Divi’s Labs Q2 results for net profit?
Divi’s Labs Q2 results showed net profit of ₹1,127 crore, up 64% from around ₹687 crore in the same quarter a year earlier.
Why did Divi’s Laboratories’ profit grow so much this quarter?
Better margins from custom synthesis work, steadier raw material costs, a favourable rupee-dollar rate, and stronger capacity utilisation all contributed to the jump.
Is Divi’s Labs involved in GLP-1 drug manufacturing?
Divi’s has been building out custom synthesis capability for global innovator companies, and the GLP-1 class of weight-loss and diabetes drugs is widely seen as one of the bigger opportunities for Indian CRAMS players right now.
What is Divi’s Laboratories’ main business?
Divi’s Laboratories makes active pharmaceutical ingredients (APIs), custom-synthesised intermediates for innovator drugmakers, and nutraceutical ingredients, and it exports a large share of what it produces.
Where is Divi’s Labs based?
The company is headquartered in Hyderabad, with major manufacturing units in Andhra Pradesh and Telangana.
Bottom line: the Divi’s Labs Q2 results are a clean beat, and they land at a moment when Indian API makers are trying to prove they can be more than a backup plan for global pharma. If the next couple of quarters hold this margin trend, that argument gets a lot easier to make.